UniQure moved to secure regulatory momentum for Huntington’s disease, submitting applications to the FDA and the UK’s MHRA for AMT-130 and requesting priority review. The company is seeking accelerated approval based on previously reported three-year data showing slowed disease progression, after earlier FDA concerns forced changes to how UniQure structured its evidence package.